US Patent 11142799 Detecting chromosomal aberrations associated with cancer using genomic sequencing
Patent 11142799 was granted and assigned to The Chinese University of Hong Kong Chorus on October, 2021 by the United States Patent and Trademark Office.
All edits
Methods, systems, and apparatus determine whether a first chromosomal region exhibits a deletion or an amplification associated with cancer in a sample from a subject (e.g., where the sample includes a mixture of cell-free DNA from tumor cells and non-malignant cells. Nucleic acid molecules of the biological sample are sequenced. Respective amounts of a clinically-relevant chromosomal region and of background chromosomal region(s) are determined from results of the sequencing. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether first chromosomal region exhibits a deletion or an amplification associated with cancer.
US Patent 11142799 Detecting chromosomal aberrations associated with cancer using genomic sequencing
Find more entities like US Patent 11142799 Detecting chromosomal aberrations associated with cancer using genomic sequencing
